Interpace Diagnostics Announces New Data Analyzing Imbalance of Short Tandem Repeat Alleles for Pancreatic Cancer Detection Published as an ASCO 2024 Abstract Jun 4, 2024
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results Mar 7, 2024
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results Aug 9, 2023
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement Jul 10, 2023
Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023 Jun 5, 2023
Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results May 12, 2023
Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results Mar 27, 2023
Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern Nov 14, 2022